2/2
05:15 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
2/1
01:05 am
ptgx
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
Medium
Report
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
1/30
07:02 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/7
09:28 pm
ptgx
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
Medium
Report
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
1/7
06:21 pm
ptgx
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]
Medium
Report
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]
1/5
09:10 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $110.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $110.00 price target on by analysts at Truist Financial Corporation.
1/5
07:40 am
ptgx
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) [Yahoo! Finance]
Low
Report
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) [Yahoo! Finance]
12/25
04:12 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
12/17
07:19 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/8
07:22 am
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/5
04:43 pm
ptgx
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory [Yahoo! Finance]
Low
Report
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory [Yahoo! Finance]
11/10
05:18 pm
ptgx
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
Low
Report
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.